ASA: Brand X shows sustained BP control at 5 Years
November 9, 2023
BRANDTON, KS - New long-term results from an open-label clinical trial show Brand X (fictusapril) provides sustained blood pressure lowering and consistent efficacy over a 5-year period. The findings were presented this week at the American Society of Hypertension (ASH) Annual Meeting.
The study followed 785 patients with hypertension who were treated with Brand X for up to 5 years. Patients were started on Brand X treatment and followed for up to 60 months.
Results showed clinically meaningful reduction in both systolic and diastolic blood pressure was maintained consistently over the entire 60 month follow-up, with no attenuation.
"This latest long-term data demonstrates the durable efficacy of Brand X in providing sustained blood pressure control beyond 24 hours for up to 5 years," said lead investigator Dr. James Able.
The safety and tolerability of long-term Brand X therapy remained favorable over the course of the study. The most common adverse events were dizziness, headache, and upper respiratory infections.
“This adds to the evidence of Brand X as a compelling first-line treatment option with proven ability to effectively lower blood pressure on a continuous basis, long after initial treatment period," said CEO of Pharma Co AG.
View the clinical study summary
To view the LongTerm-HTN: 5-year trial clinical study summary, click here.